Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kinetics of COVID-19-neutralising Antibodies in EHPAD/USLD Residents
NCT04563650Active, not recruiting
- Sponsor
- CHU Amiens-Picardie
- Start
- Aug 2020
- Primary completion
- Mar 2021
- Countries
- 1
01
Overview
Trial (2 arms), sponsored by CHU Amiens-Picardie. Primary endpoint: Titers of COVID-19 neutralizing antibodies at 9 months. Started Aug 2020; status: active, not recruiting.
Beyond the preview
Go deeper on NCT04563650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04563650.